We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+1.98%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$489M
AUM Growth
+$31.8M
Cap. Flow
+$69.7M
Cap. Flow %
14.26%
Top 10 Hldgs %
49.33%
Holding
85
New
24
Increased
27
Reduced
16
Closed
16
Avg Time Held Equity + Options
3.6 quarters
Top 10 Avg Time Held Equity + Options
2.2 quarters
Top 20 Avg Time Held Equity + Options
2.8 quarters
Avg Time Held Equity only
3.7 quarters
Top 10 Avg Time Held Equity only
2.2 quarters
Top 20 Avg Time Held Equity only
2.9 quarters

Top Buys

Rank Stock Value
1
ETNB icon
89bio
ETNB
+$12.4M
2
KALV icon
KalVista Pharmaceuticals
KALV
+$11.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$9.19M
4
SLNO icon
Soleno Therapeutics
SLNO
+$8.1M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$7.71M

Top Sells

Rank Stock Value
1
PLRX icon
Pliant Therapeutics
PLRX
+$17.3M
2
ITCI icon
Intra-Cellular Therapies Inc.
ITCI
+$15M
3
PSTX icon
Poseida Therapeutics, Inc. Common Stock
PSTX
+$9.72M
4
SRRK icon
Scholar Rock
SRRK
+$7.92M
5
COGT icon
Cogent Biosciences
COGT
+$7.18M

Sector Composition

Rank Sector Weight
1 Healthcare 97.88%
2 Miscellaneous 2.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
VRNA
1
DELISTED
Verona Pharma
VRNA
$34.7M 7.09%
545,872
+29,858
+6% +$1.79M
2024 Q1
4 quarters
MRUS icon
2
DELISTED
Merus
MRUS
$34.1M 6.98%
811,021
+130,176
+19% +$5.68M
2021 Q1
16 quarters
NUVL icon
3
DELISTED
Nuvalent
NUVL
$31.1M 6.37%
439,018
+39,004
+10% +$3.05M
2023 Q4
5 quarters
AKRO icon
4
DELISTED
Akero Therapeutics
AKRO
$29.1M 5.96%
719,992
-19,571
-3% -$830K
2022 Q2
11 quarters
INSM icon
5
Insmed
INSM
$21.1B
$24.5M 5.01%
321,366
-50,864
-14% -$3.89M
2020 Q4
17 quarters
KALV icon
6
DELISTED
KalVista Pharmaceuticals
KALV
$19.6M 4.01%
1,698,984
+1,086,811
+178% +$11.1M
2023 Q1
8 quarters
VCYT icon
7
Veracyte
VCYT
$3.47B
$18.8M 3.84%
633,832
+130,551
+26% +$4.98M
2021 Q1
16 quarters
RYTM icon
8
Rhythm Pharmaceuticals
RYTM
$5.96B
$17.9M 3.66%
337,605
+63,709
+23% +$3.53M
2023 Q2
7 quarters
SNDX icon
9
Syndax Pharmaceuticals
SNDX
$1.25B
$16.1M 3.29%
1,309,224
+78,824
+6% +$1.11M
2024 Q2
3 quarters
URGN icon
10
UroGen Pharma
URGN
$1.87B
$15.3M 3.12%
1,381,158
+260,685
+23% +$2.78M
2023 Q3
6 quarters
RNAM
11
DELISTED
Avidity Biosciences
RNAM
$12.1M 2.48%
411,312
-132,339
-24% -$4.12M
2024 Q1
4 quarters
SLNO icon
12
DELISTED
Soleno Therapeutics
SLNO
$11.9M 2.43%
+166,417
New +$8.1M
2025 Q1
0 quarters
ASND icon
13
Ascendis Pharma A/S
ASND
$14.7B
$11.8M 2.41%
75,751
+24,260
+47% +$3.47M
2024 Q3
2 quarters
IRON icon
14
Disc Medicine
IRON
$2.17B
$11.7M 2.4%
236,471
+126,090
+114% +$7.01M
2024 Q2
3 quarters
ORIC icon
15
Oric Pharmaceuticals
ORIC
$1.17B
$11.5M 2.35%
2,060,240
+881,940
+75% +$7.71M
2022 Q2
11 quarters
ETNB icon
16
DELISTED
89bio
ETNB
$11M 2.25%
1,510,498
+1,413,987
+1,465% +$12.4M
2023 Q1
8 quarters
ERAS icon
17
Erasca
ERAS
$5.17B
$10.1M 2.06%
7,367,996
-175,905
-2% -$302K
2024 Q1
4 quarters
WVE icon
18
Wave Life Sciences
WVE
$619M
$8.49M 1.74%
1,050,374
+441,477
+73% +$4.83M
2024 Q1
4 quarters
NBIX icon
19
Neurocrine Biosciences
NBIX
$13.7B
$8.03M 1.64%
+72,583
New +$9.19M
2025 Q1
0 quarters
TVTX icon
20
Travere Therapeutics
TVTX
$4.88B
$7.33M 1.5%
408,849
+131,484
+47% +$2.67M
2024 Q4
1 quarter
AKRO icon
21
CALL
DELISTED
Akero Therapeutics
AKRO
$7.31M 1.5%
180,600
-39,400
-18% -$1.67M
2024 Q4
1 quarter
GOSS icon
22
Gossamer Bio
GOSS
$59.7M
$6.95M 1.42%
79,009
+1,861
+2% +$172K
2023 Q3
6 quarters
GILD icon
23
Gilead Sciences
GILD
$183B
$6.95M 1.42%
62,029
+52,029
+520% +$5.37M
2024 Q4
1 quarter
BBOT icon
24
BridgeBio Oncology
BBOT
$237M
$6.93M 1.42%
613,393
+100,024
+19% +$1.08M
2024 Q1
4 quarters
ELUT icon
25
Elutia
ELUT
$34.2M
$6.76M 1.38%
2,670,056
+887,785
+50% +$2.68M
2024 Q1
4 quarters
1
2 3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Silverarc Capital Management held 85 positions worth $489M, up 7% from $457M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Silverarc Capital Management deployed $69.7M of net new capital in Q1 2025, opening 24 new positions and adding to 27 existing holdings. Its largest new stake was Neurocrine Biosciences: 72,583 shares worth $8.03M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Centessa Pharmaceuticals, an estimated $5.99M trimmed.

  • Silverarc Capital Management's largest Q1 2025 buy was Neurocrine Biosciences: 72,583 shares worth $8.03M.
  • Silverarc Capital Management added most to 89bio in Q1 2025, an estimated $12.4M increase.
  • Silverarc Capital Management's biggest Q1 2025 reduction was Centessa Pharmaceuticals, cutting an estimated $5.99M.
  • Silverarc Capital Management fully exited Pliant Therapeutics in Q1 2025, selling an estimated $17.3M.
  • Silverarc Capital Management's ten largest holdings make up 49% of its $489M portfolio in Q1 2025.
  • Silverarc Capital Management opened 24 new positions and closed 16 in Q1 2025.
  • Silverarc Capital Management's portfolio value rose 7% quarter-over-quarter to $489M.

Based on Silverarc Capital Management's 13F filing for Q1 2025, filed 14 May 2025.